Keywords:
brain
;
tumor
;
evaluation
;
Germany
;
imaging
;
TUMORS
;
TIME
;
PATIENT
;
primary
;
BODY-WEIGHT
;
CONTRAST
;
INJECTION
;
MR
;
ACQUISITION
;
EFFICACY
;
metastases
;
PARAMETERS
;
STATISTICAL-ANALYSIS
;
MORPHOLOGY
;
SAFETY
;
CENTRAL-NERVOUS-SYSTEM
;
CONTRAST AGENTS
;
DOUBLE-BLIND
;
GADOBENATE-DIMEGLUMINE
;
GADODIAMIDE INJECTION
;
GADOPENTETATE DIMEGLUMINE
;
INTRACRANIAL METASTASES
;
gadobenate dimeglumine
;
MR imaging
;
VASCULARIZATION
;
GLIOMAS
;
ENHANCED MRI
;
brain neoplasms,MR,gadolinium,magnetic resonance (MR),contrast media
;
HIGH-DOSE GADOTERIDOL
;
MAGNEVIST GD-DTPA
Abstract:
PURPOSE: To evaluate the safety of and compare the enhancement characteristics of gadobenate dimeglumine (MultiHance; Bracco Imaging, Milan, Italy) with those of a standard gadolinium chelate (gadopentetate dimeglumine, Magnevist; Schering, Berlin, Germany) in primary and secondary brain tumors on the basis of qualitative and quantitative parameters, on an intraindiviual basis.MATERIALS AND METHODS: Twenty-seven patients with either high-grade glioma or metastases were enrolled in a bicentric intraindividual crossover study to compare lesion enhancement with doses of 0.1 mmol per kilogram of body weight of 0.5 mol/L gadopentetate dimeglumine and 0.5 mol/L gadobenate dimeglumine. MR imaging was performed before injection (T1-weighted spin-echo [SE] and T2-weighted fast SE acquisitions) and at 1, 3, 5, 7, 9, and 16 minutes after injection (T1-weighted SE acquisitions). Qualitative assessment was performed by blinded off-site readers (for 22 patients) and on-site investigators (for 24 patients) in terms of global contrast enhancement, lesion-to-brain contrast, lesion delineation, internal lesion morphology and structure, tumor vascularization, and global image preference. Additional quantitative assessment with region-of-interest analysis was performed by off-site readers alone. Statistical analysis of qualitative data was performed with the Wilcoxon signed rank test, whereas a nonparametric approach was adopted for analysis of quantitative data.RESULTS: Significant (P 〈 .05) preference for gadobenate dimeglumine over gadopentetate dimeglumine was noted both off-site and on-site for the global assessment of contrast enhancement. For off-site readers I and 2 and the on-site investigators, respectively, gadobenate dimeglumine was preferred in 13, 17, and 16 patients; gadopentetate dimeglumine was preferred in four, four, and four patients; and equality was found in five, one, and four patients). Similar preference for gadobenate dimeglumine was noted by off-site readers and on-site investigators for lesion-to-brain contrast and all other qualitative parameters. Off-site quantitative evaluation revealed significantly (P 〈 .05) superior enhancement for gadobenate dimeglumine compared with that for gadopentetate dimeglumine at all time points from 3 minutes after injection.CONCLUSION: Significantly superior contrast enhancement of intraaxial enhancing brain tumors was achieved with 0.1 mmol/kg gadobenate dimeglumine compared with that with 0.1 mmol/kg gadopentetate dimeglumine. (C) RSNA, 2004
Type of Publication:
Journal article published
Deep Link:
http://www.dkfz.de/cgi-bin/sel?http://www.dkfz.de/PublicationManager/Show/ShowJournal.aspx%3fpublishedId=1324
Permalink
